Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb;11(2):135–149. doi: 10.21037/tlcr-21-815

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2022 Translational Lung Cancer Research. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

Comparison of the Kaplan-Meier estimates of patients with max BTS ≥50 mm who received ICI-mono and ICI-chemo. (A) PFS (n=90). (B) OS (n=90). (C) PFS with PD-L1 score ≥50% group (n=51). (D) OS with PD-L1 score ≥50% group (n=51). BTS, baseline tumor size; max BTS, maximum BTS; ICI, immune checkpoint inhibitor; ICI-mono, ICI monotherapy; ICI-chemo, ICI in combination with chemotherapy; PFS, progression-free survival; OS, overall survival; PD-L1, programmed death ligand-1; HR, hazard ratio; CI, confidence interval.